Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, has entered into an agreement with Columbia University to extend its current research partnership efforts. The agreement outlines certain assets that are currently under development regarding the work of associate professor of clinical Neurobiology Dr. Christine Ann Denny at Columbia University Irving Medical Center. Denny and her team are studying the molecular mechanisms underlying learning and memory, including diseases such as Alzheimer’s disease. According to the announcement, Denny’s pioneering research is evaluating whether ketamine and novel inventions associated with the substance have potential to improve memory retrieval as well as halt or even reverse the process of memory loss and cognitive aging related to Alzheimer’s. “The first steps of our research with Columbia have been positive, and we’re happy to extend this research and option pact to continue the progress of SPC-14 as an Alzheimer’s therapeutic and SPC-15 for stress-induced anxiety disorders,” said Silo Pharma CEO Eric Weisblum in the press release.
To view the full press release, visit https://ibn.fm/RgX6q
About Silo Pharma Inc.
Silo Pharma is a developmental-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research indications such as Alzheimer’s, PTSD and other rare neurological disorders. Silo’s mission is to identify assets to license and fund the research, which the company believes will be transformative to the well-being of patients and the health-care industry. For more information about the company, visit www.SiloPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to SILO are available in the company’s newsroom at https://ibn.fm/SILO
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)
For more information please visit https://www.psychedelicnewswire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.
